Journal of Stem Cell & Regenerative Medicine
Online Journal of Stem Cell & Regenerative Medicine

German Stem Cell Society to Support the JSRM. Decision taken in the General Body of GSS on the 3rd Nov 2006, Cologne, Germany.

 
Autologous Immune Enhancement Therapy

JSRM: an exclusive and free online journal is the official organ of
German Stem Cell Society.

JSRM Vol 1. Issue 1
Subscribe for the Online JSRM
Why Subscribe?
Powerful research and list-building tools provide enterprise-wide value.
Click here to subscribe

Inaugural Issue; Vol.1  Issue: 1: Abstract: PASRM 2006-006 (JSRM code: 001010700012)

Treatments of Liver Failure in Japan

Fujii H1, Matsuda M1

@

1 Yamanashi University-School of Medicine, Tamaho, Japan

(PASRM** 2006-006)

Liver failure is a fatal disease. Common causative disease of liver failure in Japan are end-stage liver disease due to cirrhosis and /or hepatocellular carcinoma (HCC), fulminant hepatitis and postoperative liver failure.

 As for postoperative liver failure, operative mortality after hepatic resection for HCC decreased from 2.3% in 1990-1991 to 0.6% in 1998-1999 in Japan. According to a nationwide survey of patients with potentially fatal fulminate hepatitis in 1998, the etiology was hepatitis A viral (HAV) infection in 4%, hepatitis B viral (HBV) infection in 44%, and nonA-nonB in 41 in Japan.

Most of the Japanese doctors believe that plasma exchange (PE) and continuous hemodiafiltration (CHDF) are the most effective therapies for the treatment of acute liver failure, but randomized controlled studies are needed to determine their effects.

 Liver transplantation is the only established treatment for liver failure, however, donor shortage remain problematic. Furthermore, cadaveric liver tranplantations are unsuited to the social mores of Japanese culture. In 1988 living donor liver transplantation was performed for the first time in Japan. Many Japanese patients with fulminant hepatic failure or end-stage cirrhosis were treated by living donor liver transplantation nowadays.

 Bioartificial liver supports are being considered as the second line of treatment for liver failure.

@

Corresponding Author: Dr. Hideki Fujii, Professor & Head, Ist Dept. of Surgery, Yamanashi University-School of Medicine, 1110, Shimokatoh, Tamaho 409-3898, Japan. hfujii@yamanashi.ac.jp Tel: +81-55-2731111

@

** Proceedings of Annual Symposium on Regenerative Medicine

 

 

Back to index page
Creative Commons License This is an open-access article distributed under the terms of the Creative Commons 3.0 Unported (CC BY 3.0) Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Copyright © Journal of Stem Cells & Regenerative Medicine. All rights reserved.
Disclaimer